Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 23 studies | 29% ± 8% | |
plasmacytoid dendritic cell | 15 studies | 43% ± 14% | |
astrocyte | 14 studies | 34% ± 14% | |
oligodendrocyte | 13 studies | 36% ± 14% | |
oligodendrocyte precursor cell | 12 studies | 40% ± 14% | |
glutamatergic neuron | 11 studies | 55% ± 21% | |
GABAergic neuron | 10 studies | 56% ± 20% | |
adipocyte | 10 studies | 55% ± 20% | |
neuron | 6 studies | 48% ± 24% | |
endothelial cell | 6 studies | 36% ± 20% | |
interneuron | 6 studies | 69% ± 15% | |
connective tissue cell | 5 studies | 27% ± 13% | |
smooth muscle cell | 5 studies | 18% ± 2% | |
amacrine cell | 5 studies | 34% ± 7% | |
epithelial cell | 5 studies | 30% ± 17% | |
pericyte | 4 studies | 32% ± 20% | |
granule cell | 4 studies | 41% ± 13% | |
Mueller cell | 4 studies | 26% ± 7% | |
myofibroblast cell | 3 studies | 23% ± 7% | |
GABAergic interneuron | 3 studies | 53% ± 14% | |
glial cell | 3 studies | 42% ± 10% | |
progenitor cell | 3 studies | 50% ± 13% | |
GABAergic amacrine cell | 3 studies | 55% ± 5% | |
glycinergic amacrine cell | 3 studies | 33% ± 4% | |
ependymal cell | 3 studies | 29% ± 18% | |
adventitial cell | 3 studies | 31% ± 7% | |
Schwann cell | 3 studies | 40% ± 10% | |
basal cell | 3 studies | 38% ± 17% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 8435.26 | 180 / 180 | 98% | 61.00 | 423 / 430 |
prostate | 100% | 7866.92 | 245 / 245 | 98% | 38.55 | 491 / 502 |
brain | 94% | 5756.39 | 2486 / 2642 | 99% | 85.63 | 698 / 705 |
skin | 99% | 4598.32 | 1792 / 1809 | 94% | 43.66 | 443 / 472 |
thymus | 100% | 7705.36 | 652 / 653 | 88% | 23.57 | 531 / 605 |
breast | 100% | 8943.61 | 459 / 459 | 87% | 24.02 | 974 / 1118 |
adrenal gland | 99% | 5106.55 | 255 / 258 | 86% | 30.40 | 198 / 230 |
lung | 99% | 6807.92 | 572 / 578 | 79% | 25.35 | 913 / 1155 |
uterus | 100% | 8256.37 | 170 / 170 | 77% | 24.04 | 355 / 459 |
esophagus | 99% | 5617.19 | 1434 / 1445 | 73% | 38.97 | 133 / 183 |
pancreas | 99% | 3396.52 | 326 / 328 | 69% | 12.13 | 122 / 178 |
kidney | 82% | 2295.75 | 73 / 89 | 76% | 15.68 | 689 / 901 |
bladder | 100% | 7853.71 | 21 / 21 | 55% | 13.59 | 279 / 504 |
stomach | 99% | 4563.70 | 355 / 359 | 38% | 8.78 | 108 / 286 |
intestine | 94% | 4706.34 | 911 / 966 | 20% | 4.22 | 106 / 527 |
ureter | 0% | 0 | 0 / 0 | 100% | 32.50 | 1 / 1 |
adipose | 100% | 11205.15 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 5931.09 | 1333 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 30.61 | 79 / 80 |
spleen | 91% | 2262.60 | 220 / 241 | 0% | 0 | 0 / 0 |
heart | 90% | 4460.27 | 772 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 87% | 36.53 | 39 / 45 |
muscle | 83% | 1785.61 | 667 / 803 | 0% | 0 | 0 / 0 |
liver | 17% | 259.03 | 39 / 226 | 16% | 3.52 | 63 / 406 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.30 | 1 / 29 |
peripheral blood | 3% | 61.97 | 29 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0021766 | Biological process | hippocampus development |
GO_0006470 | Biological process | protein dephosphorylation |
GO_0050804 | Biological process | modulation of chemical synaptic transmission |
GO_0099537 | Biological process | trans-synaptic signaling |
GO_0061000 | Biological process | negative regulation of dendritic spine development |
GO_0021510 | Biological process | spinal cord development |
GO_0032687 | Biological process | negative regulation of interferon-alpha production |
GO_0099560 | Biological process | synaptic membrane adhesion |
GO_0035335 | Biological process | peptidyl-tyrosine dephosphorylation |
GO_0010977 | Biological process | negative regulation of neuron projection development |
GO_0022038 | Biological process | corpus callosum development |
GO_0032688 | Biological process | negative regulation of interferon-beta production |
GO_0021549 | Biological process | cerebellum development |
GO_0034164 | Biological process | negative regulation of toll-like receptor 9 signaling pathway |
GO_0090557 | Biological process | establishment of endothelial intestinal barrier |
GO_0030517 | Biological process | negative regulation of axon extension |
GO_0021987 | Biological process | cerebral cortex development |
GO_0048681 | Biological process | negative regulation of axon regeneration |
GO_0048671 | Biological process | negative regulation of collateral sprouting |
GO_0099151 | Biological process | regulation of postsynaptic density assembly |
GO_0098978 | Cellular component | glutamatergic synapse |
GO_0098839 | Cellular component | postsynaptic density membrane |
GO_0098685 | Cellular component | Schaffer collateral - CA1 synapse |
GO_0005886 | Cellular component | plasma membrane |
GO_0043204 | Cellular component | perikaryon |
GO_0030672 | Cellular component | synaptic vesicle membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0042734 | Cellular component | presynaptic membrane |
GO_0005829 | Cellular component | cytosol |
GO_0030426 | Cellular component | growth cone |
GO_0030424 | Cellular component | axon |
GO_0008201 | Molecular function | heparin binding |
GO_0004721 | Molecular function | phosphoprotein phosphatase activity |
GO_0043395 | Molecular function | heparan sulfate proteoglycan binding |
GO_0035374 | Molecular function | chondroitin sulfate binding |
GO_0005515 | Molecular function | protein binding |
GO_0004725 | Molecular function | protein tyrosine phosphatase activity |
Gene name | PTPRS |
Protein name | PTPRS protein (Protein tyrosine phosphatase receptor type S) Alternative protein PTPRS Receptor-type tyrosine-protein phosphatase S (R-PTP-S) (EC 3.1.3.48) (Receptor-type tyrosine-protein phosphatase sigma) (R-PTP-sigma) Receptor-type tyrosine-protein phosphatase F protein-tyrosine-phosphatase (EC 3.1.3.48) |
Synonyms | |
Description | FUNCTION: Cell surface receptor that binds to glycosaminoglycans, including chondroitin sulfate proteoglycans and heparan sulfate proteoglycan . Binding to chondroitin sulfate and heparan sulfate proteoglycans has opposite effects on PTPRS oligomerization and regulation of neurite outgrowth. Contributes to the inhibition of neurite and axonal outgrowth by chondroitin sulfate proteoglycans, also after nerve transection. Plays a role in stimulating neurite outgrowth in response to the heparan sulfate proteoglycan GPC2. Required for normal brain development, especially for normal development of the pituitary gland and the olfactory bulb. Functions as a tyrosine phosphatase . Mediates dephosphorylation of NTRK1, NTRK2 and NTRK3 (By similarity). Plays a role in down-regulation of signaling cascades that lead to the activation of Akt and MAP kinases (By similarity). Down-regulates TLR9-mediated activation of NF-kappa-B, as well as production of TNF, interferon alpha and interferon beta . . |
Accessions | G8JL96 ENST00000262963.11 [Q13332-1] Q13332 ENST00000588012.5 [Q13332-6] L8E8Y3 ENST00000262963 ENST00000590509.5 ENST00000592099.5 [Q13332-7] A8E4L7 L8EAN4 Q8NHS7 ENST00000587303.5 [Q13332-1] |